Skip to search formSkip to main contentSkip to account menu

New Approaches to Brain Tumor Therapy Consortium

Known as: NABTT 
The primary objective of the "New Approaches to Brain Tumor Therapy (NABTT)" CNS Consortium is to improve the therapeutic outcome for adults with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States.
2003 Background: Many novel agents are being studied in combination with radiation and temozolomide (RT+TMZ) in newly diagnosed… 
2016
2016
A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18-month survival data (NABTT 0501).
2002 Background: Polyinosinic-polycytidylic (poly-ICLC), is a double-stranded RNA that stimulates a variety of host defense… 
2016
2016
Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma.
2039 Background: Platelet-derived growth factor signaling is important in gliomagenesis and PDGFR-β is expressed on >90% of… 
2008
2008
Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
2043 Background: Rituximab, a chimeric monoclonal antibody against the CD20 antigen, improves survival when combined with CHOP… 
2005
2005
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, headache, and nausea.
N Engl J Med 2005;352:185-94. Copyright © 2005 Massachusetts Medical Society. A 35-year-old woman was admitted to the emergency… 
2005
2005
Intratumoral pharmacokinetics determined with microdialysis in a patient with glioblastoma multiforme following systemic administration of high dose methotrexate
1569 Background: The delivery of therapeutic concentrations of chemotherapeutic agents to brain tumors remains a major concern in… 
2005
2005
NABTT 2105: A phase I dose-escalation trial of GliaSite brachytherapy with conventional radiation therapy for newly diagnosed glioblastoma multiforme
1570 Background: NABTT opened trial 2105 to determine the maximum tolerated dose (MTD) of GliaSite Brachytherapy (GSBT) with… 
2005
2005
NABTT 2111: A phase I trial of BMS-247550 for patients with recurrent high-grade gliomas
1563 Background: BMS-247550 is a semi-synthetic analog of epothilone B, a novel non-taxane microtubule-stablizing agent. A phase… 
2004
2004
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in… 
2004
2004
Phase II trial of copper depletion as angiosuppressive treatment in newly diagnosed Glioblastoma Multiforme: Final report.
1530 Background: Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)